Evidence map›Paper›PMID 28527102›Full record

ArticleNeurotoxicity research2018

Studies of Environmental Risk Factors in Amyotrophic Lateral Sclerosis (ALS) and a Phase I Clinical Trial of L-Serine.

Walter G Bradley, R X Miller, T D Levine, E W Stommel, P A Cox

Abstract readClinical Trial, Phase IMulticenter Study
PubMed Publisher
In one paragraph

Article in Neurotoxicity research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. ALS risk factors: Industrial airborne chemical releases.Environmental pollution (Barking, Essex : 1987) · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Walter G BradleyDepartment of Neurology, Miller School of Medicine, University of Miami, 1717 N Bayshore Drive, Apt 3134, Miami, FL, 33132, USA. w.bradley@miami.edu.
R X MillerForbes Norris MDA/ALS Research and Treatment Center, California Pacific Medical Center, San Francisco, CA, USA.
T D LevinePhoenix Neurological Associates, Phoenix, AZ, USA.
E W StommelDepartment of Neurology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
P A CoxBrain Chemistry Labs, Institute for Ethnomedicine, Jackson, WY, USA.
California Pacific Medical Center · USDartmouth College · USInstitute for EthnoMedicine · USPhoenix Neurological Associates · USUniversity of Miami · US

Funding

Agency for Toxic Substances and Disease Registry Contract 200-2014-59046Agency for Toxic Substances and Disease Registry R01TS000245-01Amyotrophic Lateral Sclerosis Association 15-IIP-213Institute for Ethnomedicine N/A
6 · The paper itself

Abstract

β-N-Methylamino-L-alanine (BMAA) has been linked to Guam ALS/PDC and shown to produce neurodegeneration in vitro and in vivo (Drosophila, mice, rats, primates). BMAA misincorporation into neuroproteins produces protein misfolding and is inhibited by L-serine. Case-control studies in Northern New England indicate that living near to water-bodies with cyanobacterial blooms increases the risk of developing amyotrophic lateral sclerosis (ALS). The distribution of addresses of ALS cases in New Hampshire, Vermont, and Florida was compared to that of controls. Areas of statistically significantly increased numbers of ALS cases were examined for sources of environmental toxins. A phase I trial of oral L-serine was performed in 20 ALS patients (0.5 to 15 g twice daily). Safety and tolerability were assessed by comparing the rate of deterioration with 430 matched placebo controls. The distribution of residential addresses of ALS cases in New England and Florida revealed many areas where the age- and gender-adjusted frequency of ALS was greater than expected (P < 0.01). GIS studies of these "hot spots" in relation to sources of environmental pollutants, like cyanobacterial blooms, Superfund and Brownfield sites, and landfills, are ongoing. In the phase I trial of L-serine, two patients withdrew from because of gastrointestinal side effects. Three patients died during the study, which was about the expected number. The ALSFRS-R in the L-serine-treated patients showed a dose-related decrease in the rate of progression (34% reduction in slope, P = 0.044). The non-random distribution of addresses of ALS patients suggests that residential exposure to environmental pollutants may play an important role in the etiology of ALS. L-Serine in doses up to 15 g twice daily appears to be safe in patients with ALS. Exploratory studies of efficacy suggested that L-serine might slow disease progression. A phase II trial is planned.

Indexed as

Amyotrophic Lateral SclerosisEnvironmental ExposureFemaleHumansMaleMiddle AgedNeuroprotective AgentsRisk FactorsSerineNeuroprotective AgentsSerineAmyotrophic lateral sclerosisBMAACyanobacteriaEnvironmental epidemiologyL-SerineTreatment

Identifiers

PMID28527102
OpenAlexW2614573405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.